TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Essex Bio-Technology ( (HK:1061) ) has issued an update.
Essex Bio-Technology Limited reported its unaudited interim financial results for the first half of 2025, showing a 5.8% increase in turnover and a 3.8% rise in profit compared to the same period in 2024. Despite a slight decline in profit margins, the company experienced growth in total assets and cash reserves, indicating a stable financial position and potential for continued investment in its core biopharmaceutical operations.
The most recent analyst rating on (HK:1061) stock is a Buy with a HK$6.50 price target. To see the full list of analyst forecasts on Essex Bio-Technology stock, see the HK:1061 Stock Forecast page.
More about Essex Bio-Technology
Essex Bio-Technology Limited operates in the biotechnology industry, focusing on the development and commercialization of biopharmaceutical products. The company primarily offers products for the treatment of wounds and eye diseases, positioning itself in the healthcare market with a focus on innovative therapies.
Average Trading Volume: 1,622,752
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.28B
For detailed information about 1061 stock, go to TipRanks’ Stock Analysis page.